Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Discussion
- BCC Lesion Criteria
3.1. Superficial
3.2. Nodular
3.3. Infiltrative
3.4. BCC Topical Treatments (Table 1)
Topical Treatment | Description | Indication |
---|---|---|
Imiquimod cream [16] | Stimulates immune response against BCC cells | Superficial or low-risk BCCs |
5-fluorouracil (5-FU) [25] | Inhibits cell growth and promotes cell death | Superficial or low-risk BCCs |
Diclofenac gel [30] | Nonsteroidal anti- inflammatory medication | Superficial or low-risk BCCs |
Ingenol mebutate gel [50] | Induces cell death and local immune Response | Superficial or low-risk BCCs |
- Imiquimod 5% Cream
- 5-fluorouracil (5-FU) Cream
3.5. AK Lesion Criteria
- AK Topical Treatments
- Tirbanibulin 1% ointment
- Diclofenac 3% non-steroidal anti-inflammatory sodium gel
4. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Tanese, K. Diagnosis and Management of Basal Cell Carcinoma. Curr. Treat. Options Oncol. 2019, 20, 13. [Google Scholar] [CrossRef] [PubMed]
- Heath, M.S. A Bar, Basal Cell Carcinoma. Dermatol. Clin. 2023, 41, 13–21. [Google Scholar] [CrossRef] [PubMed]
- Cameron, M.C.; Lee, E.; Hibler, B.P.; Giordano, C.N.; Barker, C.A.; Mori, S.; Cordova, M.; Nehal, K.S.; Rossi, A.M. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. J. Am. Acad. Dermatol. 2019, 80, 321–339. [Google Scholar] [CrossRef] [PubMed]
- Hashim, P.; Chen, T.; Rigel, D.; Bhatia, N.; Kircik, L.H. Actinic Keratosis: Current Therapies and Insights into New Treatments. J. Drugs Dermatol. 2019, 18, s161–s166. [Google Scholar] [PubMed]
- Eisen, D.B.; Asgari, M.M.; Bennett, D.D.; Connolly, S.M.; Dellavalle, R.P.; Freeman, E.E.; Goldenberg, G.; Leffell, D.J.; Peschin, S.; Wu, P.A.; et al. Guidelines of care for the management of actinic keratosis. J. Am. Acad. Dermatol. 2021, 85, e209–e233. [Google Scholar] [CrossRef]
- Navarrete-Dechent, C.; Marghoob, A.A.; Marchetti, M.A. Contemporary management of actinic keratosis. J. Dermatol. Treat. 2021, 32, 572–574. [Google Scholar] [CrossRef]
- Haque, T.; Rahman, K.M.; Thurston, D.E.; Hadgraft, J.; Lane, M.E. Topical therapies for skin cancer and actinic keratosis. Eur. J. Pharm. Sci. 2015, 77, 279–289. [Google Scholar] [CrossRef]
- McDaniel, B.; Badri, T.; Steele, R.B. Basal Cell Carcinoma. In StatPearls; StatPearls Publishing LLC: Treasure Island, FL, USA, 2022. [Google Scholar]
- Thomson, J.; Hogan, S.; Leonardi-Bee, J.; Williams, H.C.; Bath-Hextall, F.J. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst. Rev. 2020, 11, CD003412. [Google Scholar]
- Peris, K.; Fargnoli, M.C.; Garbe, C.; Kaufmann, R.; Bastholt, L.; Seguin, N.B.; Bataille, V.; Marmol, V.D.; Dummer, R.; Harwood, C.A.; et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary. Guidel. Eur. J. Cancer 2019, 118, 10–34. [Google Scholar] [CrossRef]
- Linos, E.; Chren, M.M. Active Surveillance as a Management Option for Low-risk Basal Cell Carcinoma. JAMA Intern. Med. 2021, 181, 1032–1033. [Google Scholar] [CrossRef]
- Bastiaens, M.T.; Hoefnagel, J.J.; Vermeer, B.J.; Bavinck JN, B.; Bruijn, J.A.; Westendorp, R.G. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J. Investig. Dermatol. 1998, 110, 880–884. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berking, C.; Hauschild, A.; Kölbl, O.; Mast, G.; Gutzmer, R. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch. Arztebl. Int. 2014, 111, 389–395. [Google Scholar] [PubMed] [Green Version]
- Kuo, K.Y.; Batra, P.; Cho, H.G.; Li, S.; Chahal, H.S.; Rieger, K.E.; Tang, J.Y.; Sarin, K.Y. Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. J. Am. Acad. Dermatol. 2017, 77, 233–234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tinelli, M.; Ozolins, M.; Bath-Hextall, F.; Williams, H.C. What determines patient preferences for treating low risk basal cell carcinoma when comparingsurgery vs. imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol. 2012, 12, 19. [Google Scholar] [CrossRef] [Green Version]
- Love, W.E.; Bernhard, J.D.; Bordeaux, J.S. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: A systematic review. Arch. Dermatol. 2009, 145, 1431–1438. [Google Scholar] [CrossRef]
- Verzi, A.E.; Micali, G.; Lacarrubba, F. Line-Field Confocal Optical Coherence Tomography May Enhance Monitoring of Superficial Basal Cell Carcinoma Treated with Imiquimod 5% Cream: A Pilot Study. Cancers 2021, 13, 4913. [Google Scholar] [CrossRef]
- Shaw, F.M.; Weinstock, M.A. Comparing Topical Treatments for Basal Cell Carcinoma. J. Investig. Dermatol. 2018, 138, 484–486. [Google Scholar] [CrossRef] [Green Version]
- Nanda, J.; Bermudez, R. Imiquimod. In StatPearls; StatPearls Publishing LLC: Treasure Island, FL, USA, 2021. [Google Scholar]
- Bubna, A.K. Imiquimod-Its role in the treatment of cutaneous malignancies. Indian J. Pharmacol. 2015, 47, 354–359. [Google Scholar] [CrossRef] [Green Version]
- Huang, C.M.; Kirchhof, M.G. Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review. J. Cutan. Med. Surg. 2020, 24, 495–503. [Google Scholar] [CrossRef]
- Jansen, M.H.E.; Mosterd, K.; Arits, A.H.; Roozeboom, M.H.; Sommer, A.; Essers, B.A.; van Pelt, H.P.; Quaedvlieg, P.J.; Steijlen, P.M.; Nelemans, P.J.; et al. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. J. Investig. Dermatol. 2018, 138, 527–533. [Google Scholar] [CrossRef] [Green Version]
- Arits, A.H.; Mosterd, K.; AB Essers, B.; Spoorenberg, E.; Sommer, A.; De Rooij, M.J.; van Pelt, H.P.; Quaedvlieg, P.J.; Krekels, G.A.; van Neer, P.A.; et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013, 14, 647–654. [Google Scholar] [CrossRef] [PubMed]
- Casale, J.; Patel, P. Fluorouracil. In StatPearls; StatPearls Publishing LLC: Treasure Island, FL, USA, 2021. [Google Scholar]
- Neale, H.; Michelon, M.; Jacob, S.; Pinkston, M.; Ukaegbu, R.; Zamor, W.; Morrison, E.; Deng, A.; Levin, N.A. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis. J. Am. Acad. Dermatol. 2022, 87, 423–425. [Google Scholar] [CrossRef] [PubMed]
- Paoli, J.; Gyllencreutz, J.D.; Fougelberg, J.; Backman, E.J.; Modin, M.; Polesie, S.; Zaar, O. Nonsurgical Options for the Treatment of Basal Cell Carcinoma. Dermatol. Pract. Concept. 2019, 9, 75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lebwohl, M. Actinic Keratosis. JAMA 2016, 315, 1394–1395. [Google Scholar] [CrossRef] [PubMed]
- Schmitz, L.; Broganelli, A. Boada, Classifying Actinic Keratosis: What the Reality of Everyday Clinical Practice Shows Us. J. Drugs Dermatol. 2022, 21, 845–849. [Google Scholar] [CrossRef] [PubMed]
- Dirschka, T.; Gupta, G.; Micali, G.; Stockfleth, E.; Basset-Séguin, N.; Del Marmol, V.; Dummer, R.; Jemec, G.B.E.; Malvehy, J.; Peris, K.; et al. Real-world approach to actinic keratosis management: Practical treatment algorithm for office-based dermatology. J. Dermatol. Treat. 2017, 28, 431–442. [Google Scholar] [CrossRef]
- Cornejo, C.M.; Jambusaria-Pahlajani, A.; Willenbrink, T.J.; Schmults, C.D.; Arron, S.T.; Ruiz, E.S. Field cancerization: Treatment. J. Am. Acad. Dermatol. 2020, 83, 719–730. [Google Scholar] [CrossRef] [PubMed]
- Koch, E.A.T.; Wessely, A.; Steeb, T.; Berking, C.; Heppt, M.V. Safety of topical interventions for the treatment of actinic keratosis. Expert. Opin. Drug Saf. 2021, 20, 801–814. [Google Scholar] [CrossRef]
- Gutzmer, R.; Wiegand, S.; Kölbl, O.; Wermker, K.; Heppt, M.; Berking, C. Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. Dtsch. Arztebl. Int. 2019, 116, 616–626. [Google Scholar] [CrossRef] [Green Version]
- Jansen, M.H.; Kessels, J.P.; Nelemans, P.J.; Kouloubis, N.; Arits, A.H.; van Pelt, H.P.; Quaedvlieg, P.J.; Essers, B.A.; Steijlen, P.M.; Kelleners-Smeets, N.W.; et al. Randomized Trial of Four Treatment Approaches for Actinic Keratosis. N. Engl. J. Med. 2019, 380, 935–946. [Google Scholar] [CrossRef]
- Rosso, J. Topical imiquimod therapy for actinic keratosis: Is long-term clearance a realistic benefit? J. Clin. Aesthet. Dermatol. 2008, 1, 44–47. [Google Scholar]
- Stockfleth, E.; Christophers, E.; Benninghoff, B.; Sterry, W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: A long-term follow-up study. Arch. Dermatol. 2004, 140, 1542. [Google Scholar] [CrossRef]
- Krawtchenko, N.; Roewert-Huber, J.; Ulrich, M.; Mann, I.; Sterry, W.; Stockfleth, E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-uBr. J. Dermatol. 2007, 157 (Suppl. S2), 34–40. [Google Scholar] [CrossRef]
- Schlesinger, T.; Stockfleth, E.; Grada, A.; Berman, B. Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action. Clin. Cosmet. Investig. Dermatol. 2022, 15, 2495–2506. [Google Scholar] [CrossRef] [PubMed]
- Miller, A.C.; Adjei, S.; Temiz, L.A.; Tyring, S.K. Tirbanibulin for the Treatment of Actinic Keratosis: A Review. Ski. Ther. Lett. 2022, 27, 4–7. [Google Scholar]
- Berman, B.; Grada, A.; Berman, D.K. Profile of Tirbanibulin for the Treatment of Actinic Keratosis. J. Clin. Aesthet. Dermatol. 2022, 15 (Suppl. S1), S3–S10. [Google Scholar] [PubMed]
- Mazzilli, S.; Chiara, P.; Costanza, G.; Petruzzellis, A.; Orlandi, A.; Bianchi, L.; Campione, E.; Gonzalez, S.; Pasquali, P. Overview of germline and somatic genetic alterations in basal and squamous cell carcinoma: A review of the current literature. Eur. J. Dermatol. 2021, 31, 447–456. [Google Scholar] [CrossRef]
- Newman, M.D.; Weinberg, J.M. Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis 2007, 79 (Suppl. S4), 18–28. [Google Scholar] [PubMed]
- Algarin, Y.A.; Jambusaria-Pahlajani, A.; Ruiz, E.; Patel, V.A. Advances in Topical Treatments of Cutaneous Malignancies. Am. J. Clin. Dermatol. 2023, 24, 69–80. [Google Scholar] [CrossRef]
- Kim, J.Y.S.; Kozlow, J.H.; Mittal, B.; Moyer, J.; Olencki, T.; Rodgers, P.; Bichakjian, C.; Armstrong, A.; Baum, C.; Bordeaux, J.S.; et al. Guidelines of care for the management of basal cell carcinoma. J. Am. Acad. Dermatol. 2018, 78, 540–559. [Google Scholar] [CrossRef] [Green Version]
- Cullen, J.K.; Simmons, J.L.; Parsons, P.G.; Boyle, G.M. Topical treatments for skin cancer. Adv. Drug Deliv. Rev. 2020, 153, 54–64. [Google Scholar] [CrossRef] [PubMed]
- Robinson, J.K.; Hernandez, C.; Anderson, E.R.; Nickoloff, B. Topical and light-based treatments for basal cell carcinoma. Semin. Cutan. Med. Surg. 2003, 22, 171–176. [Google Scholar] [CrossRef] [PubMed]
- Sollena, P.; Del Regno, L.; Fargnoli, M.C.; Peris, K. Topical and systemic medical treatments of basal cell carcinoma. G. Ital. Dermatol. Venereol. 2015, 150, 429–434. [Google Scholar] [PubMed]
- Herms, F.; Basset-Seguin, N. Emerging drugs for the treatment of basal cell carcinoma. Expert. Opin. Emerg. Drugs 2021, 26, 17–26. [Google Scholar] [CrossRef] [PubMed]
- Collins, A.; Savas, J.; Doerfler, L. Nonsurgical Treatments for Nonmelanoma Skin Cancer. Dermatol. Clin. 2019, 37, 435–441. [Google Scholar] [CrossRef] [PubMed]
- Mohney, L.; Singh, R.; Grada, A.; Feldman, S. Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review. J. Drugs Dermatol. 2022, 21, 60–65. [Google Scholar] [CrossRef]
- Bettencourt, M.S. Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%. Clin. Cosmet. Investig. Dermatol. 2016, 9, 205–209. [Google Scholar] [CrossRef] [Green Version]
- Bath-Hextall, F.; Ozolins, M.; Armstrong, S.J.; Colver, G.B.; Perkins, W.; Miller, P.S.J.; Williams, H.C. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): A multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014, 15, 96–105. [Google Scholar] [CrossRef]
- Jubert-Esteve, E.; Del Pozo-Hernando, L.J.; Izquierdo-Herce, N.; Bauzá-Alonso, A.; Martín-Santiago, A.; Jones-Caballero, M. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: A pilot study. Actas Dermosifiliogr. 2015, 106, 644–650. [Google Scholar] [CrossRef]
Topical Treatment | Description | Common Side Effects |
---|---|---|
5-Fluorouracil (5-FU) [31] | Inhibits DNA synthesis and cell proliferation | Local skin reactions, erythema, skin peeling, itching |
Imiquimod [31] | Induces local immune response | Local skin reactions, redness, itching, burning sensation |
Ingenol mebutate [52] | Induces cell death and inflammation | Local skin reactions, erythema, crusting, swelling |
Diclofenac [30] | Anti-inflammatory and immune- modulating | Local skin reactions, redness, itching, rash, dryness |
Tirbanibulin [37] | Disrupts microtubule network and inhibits cell division | Local skin reactions, erythema, pain or burning sensation |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tan, I.J.; Pathak, G.N.; Silver, F.H. Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States. Cancers 2023, 15, 3927. https://doi.org/10.3390/cancers15153927
Tan IJ, Pathak GN, Silver FH. Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States. Cancers. 2023; 15(15):3927. https://doi.org/10.3390/cancers15153927
Chicago/Turabian StyleTan, Isabella J., Gaurav N. Pathak, and Frederick H. Silver. 2023. "Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States" Cancers 15, no. 15: 3927. https://doi.org/10.3390/cancers15153927